| scholarly article | Q13442814 |
| consensus development conference proceedings | Q58900768 |
| P50 | author | Ming-Shiang Wu | Q39815349 |
| Yi-Chia Lee | Q57012444 | ||
| Jyh-Ming Liou | Q57065668 | ||
| Chun-Ying Wu | Q73108712 | ||
| P2093 | author name string | Deng-Chyang Wu | |
| Chun-Chao Chang | |||
| Cheng-Tang Chiu | |||
| Jaw-Town Lin | |||
| Bor-Shyang Sheu | |||
| Hsiu-Chi Cheng | |||
| Ping-I Hsu | |||
| Wei-Lun Chang | |||
| Jing-Chuan Lo | |||
| P2860 | cites work | Factors that affect life expectancy of patients with gastric adenocarcinoma | Q44156145 |
| The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer | Q44183919 | ||
| Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors | Q44480016 | ||
| High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection | Q44813868 | ||
| Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users | Q44906854 | ||
| Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients | Q45000335 | ||
| Stool antigen assay to screen H. pylori infection and to assess the success of 3-Day and 7-Day eradication therapy in the patients with partial gastrectomy | Q45038579 | ||
| Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism | Q45250885 | ||
| Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia | Q45712635 | ||
| Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands | Q46081388 | ||
| Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial | Q46107428 | ||
| Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test | Q46604889 | ||
| Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma | Q46713493 | ||
| Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption | Q46953063 | ||
| Serological responses of FldA and small-molecular-weight proteins of Helicobacter pylori: correlation with the presence of the gastric MALT tissue | Q47419092 | ||
| The Incidence of Gastric Adenocarcinoma Among Patients With Gastric Intestinal Metaplasia: A Long-term Cohort Study | Q48073089 | ||
| Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis | Q48949658 | ||
| Optimum duration of regimens for Helicobacter pylori eradication | Q24201841 | ||
| Eradication of Helicobacter pylori for non-ulcer dyspepsia | Q24246018 | ||
| Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients | Q24246267 | ||
| Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer | Q24247126 | ||
| Inflammation and cancer | Q24649640 | ||
| Kyoto global consensus report on Helicobacter pylori gastritis | Q26799430 | ||
| Diagnosis of Helicobacter pylori using the rapid urease test | Q26827589 | ||
| Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection | Q26853010 | ||
| Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis | Q28083053 | ||
| Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis | Q28166328 | ||
| Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use | Q28193290 | ||
| Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding | Q28213463 | ||
| Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial | Q28216474 | ||
| Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report | Q28264077 | ||
| Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy | Q28296156 | ||
| The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication | Q28542458 | ||
| Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration | Q29547429 | ||
| Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Q29620303 | ||
| The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults | Q30251539 | ||
| The long term results of endoscopic surveillance of premalignant gastric lesions | Q30482285 | ||
| Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia | Q31811118 | ||
| Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication | Q33302739 | ||
| Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? | Q33484552 | ||
| Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials | Q33636554 | ||
| Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection | Q33727000 | ||
| Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis | Q33993708 | ||
| Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial | Q34013156 | ||
| Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial | Q34025831 | ||
| Consensus on control of risky nonvariceal upper gastrointestinal bleeding in Taiwan with National Health Insurance | Q34100357 | ||
| Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection | Q34299125 | ||
| Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days | Q34314718 | ||
| Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. | Q34338448 | ||
| The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis | Q34443924 | ||
| Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis | Q34520598 | ||
| Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. | Q34542021 | ||
| American College of Gastroenterology guideline on the management of Helicobacter pylori infection | Q34645482 | ||
| Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials | Q34706721 | ||
| Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. | Q34737435 | ||
| Prospective comparison of H&E, Giemsa, and Genta stains for the diagnosis of Helicobacter pylori | Q34741132 | ||
| Helicobacter pylori research: historical insights and future directions | Q34764772 | ||
| Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. | Q35211999 | ||
| Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention | Q35570715 | ||
| The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study | Q35571249 | ||
| Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. | Q35841617 | ||
| 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial | Q35855301 | ||
| Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. | Q35892294 | ||
| Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. | Q35912196 | ||
| Gastritis staging in clinical practice: the OLGA staging system | Q35929516 | ||
| Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus | Q36040858 | ||
| Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users | Q36158848 | ||
| Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line | Q36357419 | ||
| Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations | Q36412858 | ||
| Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. | Q36509319 | ||
| The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. | Q36745832 | ||
| Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. | Q36820902 | ||
| Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results | Q37003878 | ||
| Asia-Pacific consensus guidelines on gastric cancer prevention | Q37101686 | ||
| Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. | Q37222737 | ||
| Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions. | Q37275837 | ||
| Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. | Q37398898 | ||
| Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability | Q37597876 | ||
| Is there an increased risk of GERD after Helicobacter pylori eradication?: a meta-analysis | Q37678186 | ||
| Helicobacter pylori infection--a boon or a bane: lessons from studies in a low-prevalence population | Q37682634 | ||
| Effects of Helicobacter pylori eradication on gastroesophageal reflux disease | Q37901543 | ||
| Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. | Q38097128 | ||
| Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection | Q38123617 | ||
| Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis | Q38194611 | ||
| Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. | Q38244069 | ||
| Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. | Q38462098 | ||
| Helicobacter pylori eradication in functional dyspepsia: HEROES trial. | Q38480411 | ||
| Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. | Q38882190 | ||
| Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial | Q39260796 | ||
| Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994 | Q39605655 | ||
| Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. | Q40809928 | ||
| Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials | Q41018165 | ||
| Distribution of intestinal metaplasia as a predictor of gastric cancer development. | Q41427237 | ||
| Performance of a one-step fecal sample-based test for diagnosis of Helicobacter pylori infection in primary care and mass screening settings. | Q41588304 | ||
| Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial | Q41606075 | ||
| Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model | Q41658544 | ||
| Helicobacter pylori test-and-treat program can be cost-effective to prevent gastric cancer in Taiwanese adults: referred to the nationwide reimbursement database | Q41670325 | ||
| Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. | Q41733681 | ||
| H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole | Q42165562 | ||
| Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance | Q42872885 | ||
| Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. | Q43081766 | ||
| Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease | Q43296117 | ||
| Diagnostic efficacy of (13)C-urea breath test for Helicobacter pylori infection in hemodialysis patients | Q43522272 | ||
| A tool to predict risk for gastric cancer in patients with peptic ulcer disease on the basis of a nationwide cohort | Q43529259 | ||
| Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients | Q43657240 | ||
| Selection of lower cutoff point of [13C]urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy | Q43754218 | ||
| Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan | Q43775988 | ||
| Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication | Q44115953 | ||
| Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. | Q50733541 | ||
| Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. | Q50896060 | ||
| Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. | Q51101883 | ||
| Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. | Q51141736 | ||
| First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. | Q51372765 | ||
| Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. | Q53122377 | ||
| Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. | Q53806593 | ||
| Clinical application of 20 MHz endosonography and anti-Helicobacter pylori immunoblots to predict regression of low-grade gastric MALToma by H. pylori eradication. | Q54787791 | ||
| Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening | Q57569869 | ||
| Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection | Q59509397 | ||
| Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers | Q61570355 | ||
| A Community-Based Study of Helicobacter pylori Therapy Using the Strategy of Test, Treat, Retest, and Re-treat Initial Treatment Failures | Q61830210 | ||
| Gastritis OLGA-staging & gastric cancer risk: a twelve year clinico-pathological follow-up study | Q61884190 | ||
| Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment | Q71085443 | ||
| Evaluation of a new urease reagent strip for detection of Helicobacter pylori in gastric biopsy specimens | Q71551357 | ||
| Declining cost-effectiveness of screening for disease. The case of gastric cancer in Japan | Q72333532 | ||
| Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan | Q72761546 | ||
| Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients | Q73023486 | ||
| Lower-dose (13)C-urea breath test to detect Helicobacter pylori infection-comparison between infrared spectrometer and mass spectrometry analysis | Q73023499 | ||
| Carbon urea breath test is not as accurate as endoscopy to detect Helicobacter pylori after gastrectomy | Q73855331 | ||
| Topographic patterns of intestinal metaplasia and gastric cancer | Q73999657 | ||
| Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention | Q77367328 | ||
| Seroprevalence of Helicobacter pylori infection among schoolchildren and teachers in Taiwan | Q80307315 | ||
| Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy | Q80720702 | ||
| The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori | Q82586852 | ||
| Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type | Q83297043 | ||
| Increased body mass index after H. pylori eradication for duodenal ulcer predisposes to erosive reflux esophagitis | Q83738272 | ||
| Endoscopic screening for gastric cancer | Q83962280 | ||
| The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis | Q84035453 | ||
| Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions | Q84943992 | ||
| Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer | Q86065616 | ||
| Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems | Q86545491 | ||
| Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia After H. pylori eradication | Q87446571 | ||
| Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy | Q95445191 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | Helicobacter pylori | Q180556 |
| disease management | Q883708 | ||
| urban ecology | Q1430301 | ||
| stomach neoplasm | Q4335552 | ||
| Helicobacter pylori infectious disease | Q4497153 | ||
| mass screening | Q64733553 | ||
| Helicobacter infection | Q65666252 | ||
| epidemiological monitoring | Q70477301 | ||
| P577 | publication date | 2017-01-08 | |
| 2017-06-01 | |||
| P1433 | published in | Helicobacter | Q15756348 |
| P1476 | title | Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale | |
| P478 | volume | 22 |
| Q91610823 | Efficacy and Long-Term Safety of H. pylori Eradication for Gastric Cancer Prevention |
| Q64911071 | Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials. |
| Q59135299 | Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication |
| Q48154249 | First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan. |
| Q46258930 | Gastric microbiota: tracing the culprit |
| Q54215879 | Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis. |
| Q50653233 | Peptic ulcer bleeding patients with Rockall scores ≥6 are at risk of long-term ulcer rebleeding: A 3.5-year prospective longitudinal study. |
| Q30239019 | Screening and treating Helicobacter pylori infection for gastric cancer prevention on the population level |
| Q91810671 | The eradication of Helicobacter pylori to prevent gastric cancer: a critical appraisal |
| Q57046942 | Toward population specific and personalized treatment of Helicobacter pylori infection |
| Q33893567 | Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy |
| Q64072046 | Vonoprazan and Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? |
Search more.